In some cancers, such as retinoblastomas [88], breast carcinomas [89], and melanomas [90], the inhibition of MDM2 may not be sufficient to stop tumor progression because the cancers highly express MDMX, which is a structural homolog of MDM2. This evidence concerns the gene MDM2 and cancer.